Polyphenon E

Drug Profile

Polyphenon E

Alternative Names: Green tea polyphenols; Polyphenon E; Polyphenon E (green tea extract); Polyphenon E Ointment; SB 03; Sinecatechins; Sinecatechins 10% ointment; Sinecatechins 15%; STA-2 - Sinphar Pharmaceutical; Veregen

Latest Information Update: 02 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsui Norin; Polyphenon Pharma
  • Developer Maastricht University; MediGene AG; Polyphenon Pharma; SynCore Biotechnology; Triton Pharma; Will-Pharma
  • Class Antineoplastics; Antivirals; Catechins; Herbal medicines
  • Mechanism of Action Antioxidants; Immunostimulants; Viral fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Genital warts
  • Phase II/III Basal cell cancer
  • Phase II Prostatic intraepithelial neoplasia
  • Preclinical Bladder cancer
  • Discontinued Actinic keratosis; Angina pectoris; Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Feb 2016 Will Pharma, MediGene AG and Maastricht University complete a phase II/III trial in Basal cell carcinoma in Netherlands (NCT02029352)
  • 05 Nov 2015 Accelis Pharma agrees to promote polyphenon E in USA for Genital warts
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top